Akt inhibitor MK-2206 enhances the effect of cisplatin in gastric cancer cells

Biomedical Reports

Volumn 4, Issue 3, 2016, Pages 365-368

  Tao, Kaixiong ^a   Yin, Yuping ^a   Shen, Qian ^b   Chen, Ying ^a   Li, Ruidong ^a   Chang, Weilong ^a   Bai, Jie ^a   Liu, Weizhen ^a   Shi, Liang ^a   Zhang, Peng ^a  

^a Tongji Medical College   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cisplatin; Gastric cancer; MK 2206; Phosphoinositide 3 kinase Akt pathway

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; CISPLATIN; DIMETHYL SULFOXIDE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B;

APOPTOSIS ASSAY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC50; MICROPLATE READER; MTT ASSAY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIOIMMUNOPRECIPITATION; STOMACH CANCER; WESTERN BLOTTING;

EID: 84993979206     PISSN: 20499434     EISSN: 20499442     Source Type: Journal    
DOI: 10.3892/br.2016.594     Document Type: Article

References (25)

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65: 5-29, 2015.
2. Power DG, Kelsen DP and Shah MA: Advanced gastric cancer-slow but steady progress. Cancer Treat Rev 36: 384-392, 2010.
3. Marin JJ, Al-Abdulla R, Lozano E, Briz O, Bujanda L, Banales JM and Macias RI: Mechanisms of resistance to chemotherapy in gastric cancer. Anticancer Agents Med Chem: Aug 3, 2015 (Epub ahead of print).
4. Kim SM and Park SH: Chemotherapy beyond second-line in advanced gastric cancer. World J Gastroenterol 21: 8811-8816, 2015.
5. Covell LL and Ganti AK: Treatment of advanced thyroid cancer: Role of molecularly targeted therapies. Target Oncol 10: 311-324, 2015.
6. Kito Y and Yamazaki K: Targeted therapies for metastatic colorectal cancer. Nihon Rinsho 73: 1384-1390, 2015 (In Japanese).
7. Wahler J and Suh N: Targeting HER2 Positive breast cancer with chemopreventive agents. Curr Pharmacol Rep 1: 324-335, 2015.
8. Chua C, Tan IB, Yamada Y, Rha SY, Yong WP, Ong WS, Tham CK, Ng M, Tai DW, Iwasa S, et al: Phase II study of trastuzumab in combination with S-1 and cisplatin in the first- line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer. Cancer Chemother Pharmacol 76: 397-408, 2015.
9. Bao Z, Cao C, Geng X, Tian B, Wu Y, Zhang C, Chen Z, Li W, Shen H and Ying S: Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis. Oncotarget: Sep 22, 2015 (Epub ahead of print).
10. Abu-Khalaf MM, Baumgart MA, Gettinger SN, Doddamane I, Tuck DP, Hou S, Chen N, Sullivan C, Lezon-Geyda K, Zelterman D, et al: Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors. Cancer 121: 1817-1826, 2015.
11. Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, et al: A parallelarm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer 111: 1932-1944, 2014.
12. Faes S and Dormond O: PI3K and AKT: Unfaithful partners in cancer. Int J Mol Sci 16: 21138-21152, 2015.
13. Guo H, German P, Bai S, Barnes S, Guo W, Qi X, Lou H, Liang J, Jonasch E, Mills GB, et al: The PI3K/AKT pathway and renal cell carcinoma. J Genet Genomics 42: 343-353, 2015.
14. Liu P, Cheng H, Roberts TM and Zhao JJ: Targeting the phos-phoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8: 627-644, 2009.
15. Shi J, Yao D, Liu W, Wang N, Lv H, Zhang G, Ji M, Xu L, He N, Shi B, et al: Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer 12: 50, 2012.
16. Matsuoka T and Yashiro M: The role of PI3K/Akt/mTOR signaling in gastric carcinoma. Cancers (Basel) 6: 1441-1463, 2014.
17. Parsons CM, Muilenburg D, Bowles TL, Virudachalam S and Bold RJ: The role of Akt activation in the response to chemo-therapy in pancreatic cancer. Anticancer Res 30: 3279-3289, 2010.
18. Lin YH, Chen BY, Lai WT, Wu SF, Guh JH, Cheng AL and Hsu LC: The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells. Naunyn Schmiedebergs Arch Pharmacol 388: 19-31, 2015.
19. Duan L, Perez RE, Hansen M, Gitelis S and Maki CG: Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1. Cancer Biol Ther 15: 1600-1612, 2014.
20. Riquelme I, Saavedra K, Espinoza JA, Weber H, García P, Nervi B, Garrido M, Corvalán AH, Roa JC and Bizama C: Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget 6: 24750-24779, 2015.
21. Benada J and Macurek L: Targeting the checkpoint to kill cancer cells. Biomolecules 5: 1912-1937, 2015.
22. Nicolini A, Ferrari P, Kotlarova L, Rossi G and Biava PM: The PI3K-AKt-mTOR pathway and new tools to prevent acquired hormone resistance in breast cancer. Curr Pharm Biotechnol 16: 804-815, 2015.
23. Pandey R and Kapur R: Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloprolif-erative neoplasms. Mol Cancer 14: 118, 2015.
24. Zhang L, Wu J, Ling MT, Zhao L and Zhao KN: The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses. Mol Cancer 14: 87, 2015.
25. Almhanna K, Cubitt CL, Zhang S, Kazim S, Husain K, Sullivan D, Sebti S and Malafa M: MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines. Cancer Biol Ther 14: 932-936, 2013.